Trials
27 active
52 in total · 33 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)”In the company’s words, NCT05405166 on ClinicalTrials.gov
- Tested for
- Plasma Cell Myeloma (3 trials), Plasma Cell Myeloma Refractory (2 trials), Plasma Cell Myeloma Recurrent, Relapsed/Refractory Multiple Myeloma
- Main trialPhase 3
- “This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who will receive at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants were randomized 1:1 into 1 of 2 study arms: Arm SC: Isatuximab SC + Pd Arm IV: Isatuximab IV + Pd Participants are allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to…”In the company’s words, NCT05405166 on ClinicalTrials.gov
- Other names
- SAR650984 · Sarclisa
Other drugs for Plasma Cell Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up5
- 1 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 5 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 13 Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Nov 2028Phase 2 trial completes · ClinicalTrials.gov
- 14 Oct 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials52
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 6 Nov 2024 | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM | |
| Phase 3Active, not recruiting | 5 Apr 2027 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | |
| Phase 3Active, not recruiting | 14 Oct 2030 | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | |
| Phase 2Active, not recruiting | 22 Dec 2025 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | |
| Phase 2Active, not recruiting | 1 Apr 2027 | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | |
| Phase 2Enrolling by invitation | 30 Nov 2028 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | |
| Phase 1/2Recruiting | 13 Sep 2027 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | |
| Phase 3Completed | 22 Nov 2018 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients | |
| Phase 3Completed | 14 Jan 2022 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients | |
| Phase 2Terminated | 14 Nov 2017 | Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia | |
| Phase 2Terminated | 12 Sep 2022 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | |
| Phase 2Terminated | 26 Jun 2023 | Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) | |
| Phase 1/2Completed | 31 Jul 2018 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients | |
| Phase 1/2Completed | 21 Dec 2018 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | |
| Phase 1/2Terminated | 10 Mar 2021 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | |
| Phase 1/2Terminated | 2 May 2022 | Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation | |
| Phase 1/2Terminated | 11 May 2022 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | |
| Phase 1/2Terminated | 8 Nov 2022 | A Study of Isatuximab-based Therapy in Participants With Lymphoma | |
| Phase 1/2Completed | 5 Apr 2023 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | |
| Phase 1Completed | 6 Sep 2020 | Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma | |
| Phase 1Completed | 26 May 2021 | SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients | |
| Phase 1Completed | 2 Dec 2021 | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma | |
| Phase 1Completed | 28 Jan 2022 | Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation | |
| Phase 1Completed | 20 Jun 2023 | SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients | |
| Phase 1Completed | 27 Mar 2024 | Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | |
| Phase 2Authorised | not given | Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/bortezomib/dexamethasone (I-VRD) followed by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followed by one cycle of high-dose therapy and maintenance therapy with lenalidomide and isatuximab | |
| Phase 3Authorised | not given | A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial) | |
| Phase 2Authorised | not given | A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemia | |
| Phase 2Authorised | not given | A Phase 2, single arm, open label, multicenter study to assess minimal residual disease after isatuximab in combination with bortezomib and lenalidomide with minimal dexamethasone in patients with newly diagnosed multiple myeloma ineligible for autologous transplant. | |
| Phase 2/3Authorised | not given | GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults with Acute Lymphoblastic Leukemia | |
| Phase 2Ended | not given | A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients _ GMMG-CONCEPT | |
| Phase 2Authorised | not given | Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma | |
| Phase 2Authorised | not given | Isatuximab and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients (Isabel study) | |
| Phase 3Authorised | not given | Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL) | |
| Phase 3Authorised | not given | A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (GMMG-HD7) | |
| Phase 2Ended | not given | A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy | |
| Phase 3Authorised | not given | MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM | |
| Phase 2Authorised | not given | ErythroSIM : Randomized prospective trial evaluating the efficacy of the antiCD38 monoclonal antibody isatuximab in the treatment of PCRA by major ABO mismatch after allogeneic hematopoietic stem cell transplantation | |
| Phase 2Authorised | not given | An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK) | |
| Phase 1/2Authorised | not given | Phase 1/2 trial evaluating isatuximab in combination with belantamab mafodotin and dexamethasone in relapsed or refractory multiple myeloma (RRMM) | |
| Phase 1/2Ended | not given | Phase 1/2 trial evaluating isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma (RRMM) previously exposed to anti-CD38 and anti-BCMA | |
| Phase 1/2Authorised | not given | Phase 1/2 trial evaluating isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma (RRMM) | |
| Phase 1/2Authorised | not given | Phase 1/2 trial evaluating isatuximab in combination with evorpacept and dexamethasone in relapsed or refractory multiple myeloma (RRMM) | |
| Phase 2Ended | not given | Isatuximab in type I cryoglobulinemia: A prospective pilot study / ICE STUDY | |
| Phase 2Authorised | not given | Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥70 years) with newly diagnosed myeloma: a randomized phase II study (SGZ-2019-12650) | |
| Phase 2Authorised | not given | A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor | |
| Phase 2Ended | not given | A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment | |
| Phase 3Ended | not given | A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma (GMMG HD8/ DSMM XIX) | |
| Phase 2Ended | not given | ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma | |
| Phase 3Authorised | not given | GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D. | |
| Phase 2Authorised | not given | ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of newly diagnosed transplant ineligible multiple myeloma | |
| Phase 3Authorised | not given | IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elderly patients (≥ 65; < 80 years). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026